Method of prevention of postpartum endometritis in cows

FIELD: veterinary medicine.

SUBSTANCE: method comprises intravaginal administration of probiotic preparation "Giprolam" (Lactobacillus fermentum 44/1 and Lactococcus lactis subsp. Lactis 574). "Giprolam" is administered for 5-7 days prior to calving daily at a dose of 100 cm3.

EFFECT: use of the claimed invention promotes to maintain the amount of lactobacilli and bifidobacteria at the physiological level, prevents the colonisation of the genital tract with potentially pathogenic microflora and prevents the occurrence of postpartum infections.

6 tbl, 2 ex

 

The invention relates to the field of animal health and for the prevention of postpartum endometritis in cows.

One of the urgent veterinary problems that reduce the profitability of the livestock of the Russian Federation, remain disease of the organs of reproduction. The frequency of their occurrence in cattle ranges from 12.0 to 60.0% and in larger farms reaches 76,0% of the number of calving cows (Methodical recommendations on the practical application of methods cryo-, ozone - and autohemotherapy and homeopathic medicines for the prevention and treatment of gynecological diseases of cows // Ivanovo: GNU Ivanovo research Institute of agriculture. - 2005. 6 C.).

The most common disease which is recorded in calving cows are postpartum endometritis. For the prevention and treatment of cows with acute postpartum endometritis, use nitrofuranovye, sulfa and antibiotic drugs in various combinations and specific biological active substances (hormones, prostaglandins and others) (Masalov, C. N., Rogozhin N. In., Arbuzov I. N. The physiological rationale for the effectiveness of different schemes of treatment and prevention of reproductive diseases in cows // Zootechnics. - 2013. - №7. - 30-31; Voitenko L., Prevention and treatment of gynecological diseases in cows // veterinary-Kuban. - 2008. No. 1. - S. 21-22).

This is now an alternative to the use of antibacterial drugs is the use of biologically active substances of natural origin, probiotic agents as the most ecologically natural competitors of pathogenic and conditionally pathogenic microflora causing endometritis in cows (Gurchenko A. N. and other Application widely used in livestock probiotic preparations for the prevention of acute postpartum endometritis in cows (in milk) // veterinary-Kuban. - 2012. No. 3. - S. 11-13.)

The known method of prevention of postpartum endometritis using biologically active drug, produced by means of biotechnology of plants of Rhaponticum carthamoides. Use of the drug intramuscularly at a dose of 2.5 ml/100 kg of body weight in dry period once every 10 days for 60, 50, 40, 30, 20 and 10 days before calving (Permyakova, I. N., Tatarnikov N. A. Biofusion and its use for the prevention of postpartum diseases of cows // Agrarian Bulletin of the Urals. - 2010. No. 11-2. - S. 41-42).

However, this method does not provide sufficient preventive effect.

Known way to prevent vaginal dysbiosis in cows in the second half of pregnancy, including the douche 2 times a day drug "Malavit and introduction intrawaginalno swab drug once a day for 10 days (E. C. Kuratov. Correction of vaginal microbiocenosis of pregnant cows with preparation Malavit" // Bulletin of the Altai state agrarian University is itata. - 2005. No. 2. - S. 53-56.

However, this method is tedious because it requires fixing each treated animal 3 times a day and duration of use of the drug for 10 days.

The known method of prevention of postpartum endometritis with the use of probiotic preparation lumenoks on the 2nd day after calving at a dose of 10.0 ml intrawaginalno within 5 days (Ivanov A. A., Zakirova C. C. the Use of probiotics for endometritis in cows // agricultural science Euro-northeast. - 2005. No. 7. - S. 128-131).

The disadvantage of this method of prevention is the need for measures to stimulate the functional activity of the uterus and removal lohii.

The known method of prevention of postpartum endometritis using probiotic preparation "Bacini" after calving in the dose of 10 ml intrauterinely 1 time a day for 3 days (N. Myasnikov.G. Antagonistic activity of probiotic preparation "Bacini" against pathogenic and conditionally pathogenic microorganisms and its prophylactic and therapeutic efficacy in endometritis cows. Abstract. Kida. Diss. - Voronezh. - 2011. - S. 25).

However, the application of probiotic after calving does not prevent the development of dysbiosis generic ways before calving, contributing to the emergence of post-partum disorders. The drug has antagonistic activity against the potential is about pathogenic microorganisms, but does not affect the quantitative content of the indigenous microflora.

Known way to prevent acute post-partum endometritis, comprising applying on the day of calving nutriceuticals probiotic preparation "Monopolin" in a dose of 40 ml per animal (Gurchenko A. N. and other Application widely used in livestock probiotic preparations for the prevention of acute postpartum endometritis in cows (in milk) // veterinary-Kuban. - 2012. No. 3. - S. 11-13.).

The known method of prevention of acute postpartum endometritis using on the day of calving nutriceuticals probiotic preparation "Sell" in a dose of 40 ml per animal (Gurchenko A. N. and other Application widely used in livestock probiotic preparations for the prevention of acute postpartum endometritis in cows (in milk) // veterinary-Kuban. - 2012. No. 3. - S. 11-13.).

However, once the use of probiotics after calving efficiency is inferior to traditionally used tools.

As a prototype of the selected method of prevention of endometritis in cows, including intravaginal administration of the drug "Giprobum" with a syringe Janet and gynecological pipette with an interval of 24 hours. The first injection should be performed within 12 hours after calving, the second 24 hours later. Preventive treatment composition which provides 2 introduction instructions for use biological drug "Giprobum" for the prevention of endometritis in cows, 2012).

However, the use of the drug cows after calving for obvious reasons, cannot prevent the development of dysbiotic condition in generic ways before calving, which is one of the leading causes of the development of postpartum diseases.

The technical result of the invention is to improve the prevention of postpartum endometritis in cows.

For this purpose, the method of prevention of postpartum endometritis in cows, including intravaginal introduction of probiotic preparation "Giprobum" (Lactobacillus fermentum 44/1 and Lactococcus lactis subsp. Lactis 574), according to the invention "Giprobum" enter daily until calving within 5-7 days at a dose of 100 cm3.

"Giprobum is a suspension light brown color, which contains viable strains of lactic acid bacteria Lactobacillus fermentum 44/1 (VKPM B-2940) and Lactococcus lactis subsp.Lactis 574(VKPM B-3145) in an amount of not less than 1×108CFU/cm3and auxiliary substances - water, whey powder, glucose, yeast extract. Included in the drug strains of lactic acid bacteria capable of prejustice in retopology ways in cows for up to 3 weeks and exert antagonistic effects on penetrating into the uterus of conditionally pathogenic flora (Staphylococcus aureus, Escherichia coli, Proteus vulgaris, Klebsiella pneumoniae and other). "Giprobum" Packed 100 cm3that is leaves one dose of the drug.

After calving in generic ways cows reduced the levels of lactobacilli and bifidobacteria, at the same time increases the number of potentially pathogenic organisms, which contributes to the development of postpartum purulent-septic diseases. Perhaps these changes in microbial landscape associated with infection vaginal microorganisms in the hotel and a large selection lohii, which is the breeding ground for microbes. The use of cows prior to calving probiotics containing lactobacilli and bifidobacteria maintain their number at the physiological level, prevents the colonization of the genital tract potentially pathogenic microflora and renders prophylactic action occurs postpartum infections.

The proposed method is as follows.

Pregnant cows for the prevention of postpartum endometritis daily until calving within 5-7 days with an interval of 24 hours intrawaginalno used probiotic preparation "Giprobum" (Lactobacillus fermentum 44/1 and Lactococcus lactis subsp. Lactis 574no 100 cm3on the animal.

To test the effectiveness of the proposed method was carried out at the dairy farm "High" LLC Conveagro" Liskinsky district, Voronezh region on cows red-and-white breed, milk yield in the previous lactation 5100-5400 kg. Way the animal is dead period group loose on deep straw bedding. 10-15 days before calving, animals were transferred to the prenatal section, and with the appearance of the forerunners of the genera in the family section, where he was calving.

The essence of the method is illustrated by examples.

Example 1. Prophylactic efficacy of the drug "Giprobum".

Cows were divided into 3 groups: 1-I, 2-I - experienced and 3rd control. Animals first experimental group (n=12) prior to calving daily for 5-7 days with an interval of 24 hours intrawaginalno used the drug "Giprobum" in a dose of 100 cm3. Animals of the second experimental group (n=12) the drug according to instructions entered twice in 12 hours after calving and after 24 hours at 100 cm3. Cows in the control group (n=12) the drug is not used.

After the cows were clinical observations, recording after calving, the number of cases of endometritis animals.

Clinical studies in the first experimental group purulent-catarrhal endometritis was detected in 2 (16.7%) in the second experimental 4 (33.3%) and control - 7 (58,3%) (table.1.).

When determining the efficiency of processing of cows "Girolamo used a performance index indicating how many times the incidence in the control group is higher than in the experimental and the performance indicator percentage, which shows directly what percentage of protected animals is a result of the treatments.

The index of effectiveness of treatments "Girolamo and its index in the first and second experimental groups were, respectively, 3.5 and 71,4%; 2 and 42,9% (table.1).

Table 1
Prophylactic efficacy of the drug "Giprobum"
Indicators5-7 days before calvingafter calvingControl
The number of animals121212
Dose100 cm3100 cm3-
Duration5-7 injections with an interval of 24 hourstwice according to the instructions for use-
The incidence of goal., %2 (16,7)4 (33,3)7 (58,3)
The performance index3,52 -
The performance indicator %71,442,9-

In the study of the microbial landscape of the generic ways in the first 2 hours after calving in cows of the control group showed a decrease in the content of lactobacilli 8 times, bifidumbakterin 10.5 times with increasing number of streptococcal group (8.8-fold), Enterococcus faecalis (4.8 times), Escherichia (14.8 times), bacteria of the genus Enterobacter (17.2) and the frequency of their selection. In addition, they isolated Staphylococcus aureus in 25% of cases (table.2).

Table 2
Microbial landscape of the genital tract of cows in the control group
Types of microorganismsNumber
5-7 days before calvingAfter calving
Lactobacilli3,55±0,71·1064,4±0,94·105
Bifidobakterii3,12±0,46·1062,96±0,68·105
Corynebacterium 2,1±0,19·1023,2±0,41·103
Staph.saprophyt.7,33±0,12·1054,11±0,81·105
Staph.epidermidis2,35±0,25·1052,1±0,17·104
Staph.aureusnot allocated2,1±0,03·104(25,0%)
Strept.the rp.C5,04±0,45·105(58,0%)to 4.41±0,81·106(58,0%)
Enteroc.faecalisto 4.73±0,22·103(50,0%)2,25±0,85·104(66,7%)
Strept.heme.4,82±0,38·105(25,0%)2,47±0,52·105(50,0%)
Enterobacter1,8±0,14·103(16,7%)3,1±,02·104(25,0%)
E. coli3,36±0,74·103(41,7%)4,96±0,65·105(58,0%)

The results of these studies indicate the imbalance of normal and potentially pathogenic microflora (violation of their quantitative ratios) in patrimonial ways cows control the nd group.

When studying the microbial landscape of the generic ways in cows, which prior to calving was used "Giprobum", the increase of the content of lactobacilli 1.2 times, bifidumbakterin 1.3 times, staphylococci: saprophytic 1.7 and epidermal 7.9 times, reducing the number of Streptococcus group With 1.2 times, Escherichia 1.6 times, and found them Enterococcus faecalis and hemolytic streptococci in 8.3% of cases (table.3).

Table 3
Microbial landscape of tribal ways of the cows that used "Giprobum"
Types of microorganismsNumber
To useAfter calving
Lactobacilli3,43±0,59·1074,34±0,61·107
Bifidobakteriito 4.41±0,72·107to 5.57±0,86·107
Corynebacterium1,8±0,02·1021,6±0,01·102
Staph.saprophyt.3,35±0,49·1055,8±0,17·105
Staph.epidermidis4,36±0,02·103(25,0%)3,43±0,74·104(50)
Staph.aureusnot allocatednot allocated
Strept.gr.C3,15±0,16·104(16,7%)2,67±0,58·104(25,0%)
Enteroc.faecalisnot allocated4,3±0,01·102(8,3%)
Strept.heme.not allocated8,1±0,01·103(8,3%)
Enterobacternot allocatednot allocated
E. coli3,27±0,89·102(25,0%)2,1±0,01·102(8,3%)

Thus, in animals, which used "Giprobum" than the s-control the number of lactobacilli and bifidobakterii was higher in 98,6 and 188,2 times, respectively. They are not allocated Staphylococcus aureus and bacteria of the genus Enterobacter. The animals were lower content of streptococcal groups in 165,2 times, Enterococcus faecalis in 52,3, hemolytic streptococci in 30.5 Escherichia 2.4·103times and frequency allocations in the 2.3-8 times.

The results of the research show about the optimal balance between normal and potentially pathogenic microflora in generic ways cows treated "Girolamo" prior to calving.

In the study of microflora of colostrum in the first days after calving found that in animals, which used "Giprobum", the number of lactobacilli and bifidobakterii was higher than in the control and 29.2 9.8 times, a Staph. epidermidis below 6.6 times, not allocated Staphylococcus aureus, Streptococcus group d, and Escherichia (PL.4).

Table 4
Microbial landscape of colostrum from cows
Name of microorganismsProcessed "Girolamo"Control
Number
Lactobacilli4,08±0,69·1044,18±0,66·103
6,82±0,65·1042,34±0,27·103
Staph. saprophyticus3,13±0,29·102(33,3%)not allocated
Staph.epidermidis6,07±0,15·102(25,0%)4,03±0,9·103(66,7%)
Staph.aureusnot allocated2,9±0,59·103(58,3%)
Strept.bovis gr.Dnot allocated3.3V±0,98·103(25,0%)
E. colinot allocated1,1±0,01·103(8,3%)

Studies suggest that the use of Girolama" cows before delivery optimizes microbial composition of colostrum, which positively affects the formation of normalize the gastrointestinal tract of newborn calves.

Example 2. Prophylactic efficacy of the drug "Giprobum".

Cows were divided into 3 groups: 1-I, 2-I experienced and 3rd control. Animals first experimental group (n=25) before calving daily for 5-7 days with an interval of 24 hours was used the drug "Giprobum" 100 cm3. Cows of the second experimental group (=25) twice injected drug "Giprobum" 100 cm 3in accordance with the manufacturer's instructions. Cows in the control group (n=25) the drug is not used.

In a clinical study in cows first experimental group purulent-catarrhal endometritis was detected in 3 (12.0 percent), the second pilot 7 (28,0%) and control 15 (60,0%) animals (table.5).

The performance index and its index in the first and second experimental groups were, respectively, 5 and 80,0%; 2,1 and 53.3% (table.5)

Table 5
Prophylactic efficacy of the drug "Giprobum"
Indicators5-7 days before calvingAfter calvingControl
The number of animals252525
Dose100 cm3100 cm3-
Duration5-7 injections with an interval of 24 hourstwice according to the instructions for use-
Ill, goal., %3 (12,0)7 (28,0)15 (60,0)
The performance index52,1-
The indicator of efficiency, %80,053,3-

Example 3. Prophylactic efficacy of the drug "Giprobum".

Cows were divided into 3 groups: 1-I, 2-I experienced and 3rd control. Animals first experimental group (n=25) daily for 5-7 days before calving with an interval of 24 hours injected drug "Giprobum" 100 cm3. Cows of the second experimental group (n=25) twice injected drug "Giprobum" after calving in the same amount. Cows in the control group (n=25) the drug is not used.

Clinical studies (table.6) installed the incidence of cows with purulent-catarrhal endometritis in the first group, in 4 (16,0%), the second experimental - 8 (32.0 per cent) and in the control and in 16 (64,0%) cases (table.6).

Table 6
Prophylactic efficacy of the drug "Giprobum"
Index"Giprobum" after calvingControl
The number of cows252525
Dose100 cm3100 cm3-
Duration5-7 injections with an interval of 24 hourstwice according to the instructions for use-
Ill, goal., %4 (16,0)8 (32,0)16 (64,0)
The performance index42-
The performance indicator %75,050,0-

The performance index and its index in the first and second experimental groups were, respectively, 4 and 75.0%; 2% and 50.0%.

Thus, the use of probiotic preparation "Giprobum" (Lactobacillus fermentum 44/1 and Lactococcus lactis subsp. Lactis 574) cows during the 7 days before calving with an interval of 24 hours intrawaginalno 100 cm 3in 71,4-80.0% of cases contributes to the prophylactics have postpartum endometritis, and after calving supported at an optimal level, the content of the indigenous microflora in generic ways and colostrum.

Method of prevention of postpartum endometritis in cows, including intravaginal introduction of probiotic preparation "Giprobum" (Lactobacillus fermentum 44/1 and Lactococcus lactis subsp. Lactis 574), wherein "Giprobum" administered for 5-7 days before calving daily dose of 100 cm3.



 

Same patents:

FIELD: veterinary medicine.

SUBSTANCE: method comprises the combined use of the tissue preparation on the 1, 3 and 5 days of treatment, and 15% solution of ASD-2f on tetrahydrovit at a dose of 10 ml intramuscularly on the 2, 4 and 6 days of treatment. The tissue preparation is used as biogenic stimulator aminoseleton which is administered subcutaneously into the upper third of the neck in increasing dose of 40-45-50 ml.

EFFECT: method is highly effective for treatment of subclinical mastitis in lactating cows.

3 tbl, 1 ex

FIELD: veterinary medicine.

SUBSTANCE: chemotherapeutic agent is used as N,N-dimethylamino-propylamides of fatty acids of the formula 1 which are used in the form of salts with pharmacologically acceptable acids.

EFFECT: use of the claimed invention is highly effective for treatment of animals with postpartum endometritis.

4 tbl, 2 ex

FIELD: veterinary medicine.

SUBSTANCE: method comprises the use of chemotherapeutic agents. The chemotherapeutic agent is used as N,N-dimethylamino-propylamides of fatty acids of the formula 1 which are used in the form of salts with pharmacologically acceptable acids.

EFFECT: use of the claimed invention is highly effective for treatment of endometritis in animals.

4 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine and medical equipment, namely to obstetrics and gynaecology, and can be used for the local treatment of inflammatory diseases of the uterine cavity. The method is implemented by inserting a waveguide of a presented device in a protection enclosure into the uterine cavity. A taper base of a narrow portion of the enclosure leans on an external orifice of the cervical uterus to prevent accidental perforation of the uterus. An infusion system regulator is used to set the spray supply of a therapeutic solution into an irrigation canal of the ultrasonic device. Thereafter ultrasonic vibrations are generated, and the uterine cavity is treated with the sounded therapeutic solution. The exposure length is 3-5 minutes at the ultrasonic vibration frequency of 25 kHz, infusion rate approximately 100-150 ml/min. The total infusion volume is not less than 300 ml. The ultrasonic treatment enables providing the continuous outflow of the uterine discharge. The device comprises an US generator, an acoustic assembly, the waveguide with the protection enclosure, the infusion system for the therapeutic solution supply. The acoustic assembly and waveguide comprises the irrigation canal. A working tip of the waveguide represents a short cylinder having a diameter greater than the rest portion. The irrigation canal of the waveguide has a diameter of 2 mm. The protection metal thin-wall enclosure has a crimped distal end and drain holes and represents two cylindrical elements of various diameters connected by a taper junction with milled grooves arranged so that to enable the fluid access to the working tip cylinder, the length of which makes no more than 3 mm.

EFFECT: inventions provide the effective cleansing of the uterine cavity from infected and necrotised tissues with improved comfort and safety of the procedure with using no endoscopic equipment, cervical dilation manipulations and uterine pre-probing.

2 cl, 3 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science, particularly to an agent for treating and preventing endometritis in animals. The substance of the invention consists as follows. Novocaine 0.5 g is dissolved in distilled water 1 l, and the following preparations are dissolved in a solution of Novocaine 250 mg: powdered metronidazole 4.0 g is dissolved in Novocaine 250 ml; powdered ciprofloxacin 2.0 g is dissolved in Novocaine 250 ml; powdered Doxycycline 1.0 g is dissolved in Novocaine 250 ml; powdered tavegil 2.5 g is dissolved in Novocaine 250 ml; all the ingredients are combined to prepare the agent in an amount of 1 litre for treating and preventing endometritis in animals.

EFFECT: invention provides the pronounced anti-inflammatory and antimicrobial effect of a broad spectrum of action combined with reducing the body response to histamine, relieving smooth muscle spasm and reducing capillary penetration.

5 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of veterinary and is intended for treatment and prevention of postpartum acute mastitis in cows. Medication contains antimicrobial, anti-inflammatory preparations and distilled water. Medication additionally contains licorice root. As antimicrobial preparation it contains metronidazole. as anti-inflammatory preparation it contains ciprofloxacin, with the following component ratio, g/l: licorice root 80-85 g; metronidazole 3.5-4.0 g; ciprofloxacin 2.0-2.5 g; distilled water - the remaining part.

EFFECT: application of claimed medication provides expressed antimicrobial and anti-inflammatory effect with simultaneous reduction of organism's response to histamine, release of spasm of smooth muscles and reduction of permeability of capillaries.

4 tbl, 10 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to obstetrics and gynaecology, and can be used for treating and managing the pregnant women suffering drug-induced hepatitis. Establishing a diagnosis of drug-induced hepatitis requires oral administration of the herbal hepatoprotectors Carsil, or Hepabene, or the vitamin-free essential phospholipids Eslidin per os or Essentiale forte N intravenously, per os in standard doses with a cessation of any other drug-induced therapy, in the 1st trimester of pregnancy in case of observing a symptom-free increase of transaminase activity within 3 normal values and no counter-indications. In the 2nd trimester, a serum transaminase level up to 5 normal values requires prescribing ademetionine 400 mg intravenously N 7-10, then per os 1,600 mg/day. The therapeutic course makes 1 month. Ademetionine 800 mg intravenously N 10 + ursodeoxycholic acid 12 mg/kg/day are prescribed if observing the daily serum transaminase level of 5 to 10 normal values. Prescribing ademetionine 800 mg/day intravenously + ursodeoxycholic acid 12 mg/kg/day + prednisolone 90 mg/day is used for the daily serum transaminase level of more than 10 normal values. In the 3rd trimester, the daily serum transaminase level of below 5 normal values requires administering ademetionine 800 mg/day intravenously N10 + ursodeoxycholic acid 13 mg/kg/day. The transaminase level of 5 to 10 normal values requires prescribing ademetionine 800 mg/day intravenously + ursodeoxycholic acid 13 mg/kg/day + prednisolone 90 mg/day intravenously. A progressive increase of the daily transaminase level of above 10 normal values with underlying therapy with ademetionine 800 mg/day intravenously, ursodeoxycholic acid 13 mg/kg/day, prednisolone 120 mg/day intravenously with 3 days expected, a decrease of the daily transaminase level or a stabilization thereof are accompanied by continuing the therapy with the progression follow-up, including hepatic cytolysis values - an increase of the hepatic cytolysis values; an increase thereof is accompanied by prescribing the adequate therapy. The postpartum therapy is continued completely until liver function tests are normalised.

EFFECT: method enables preventing the pregnancy complications ensured by the timely diagnosis of drug-induced hepatitis in the pregnant women, the adequate drug-induced therapy differentiated by gestational age and a degree of manifestation of hepatic cytolysis and aiming at reducing a hepatic pathological process.

6 ex

FIELD: medicine.

SUBSTANCE: group of inventions relates to field of veterinary. Claimed method includes obtaining antiplacental blood (APB) from young healthy horse 14 days after subcutaneous double introduction of placentolysate of cows, which contains parts of cotyledons and caruncles, with 14-day interval in dose 20 ml, and method of treatment and prevention of afterbirth retention, uterus subinvolution and postnatal endometritis in cows by application of antiplacental blood (APB), stimulating postnatal involution of genitals of newly calved cows, which is introduced subcutaneously in the area of neck two times in dose 10 ml, with 6 day interval.

EFFECT: application of antiplacental blood (APB) reduces duration of postnatal involution of genitals, which makes it possible to prevent and reduce terms of treatment of ill cows in case of afterbirth retention, uterus subinvolution and postnatal endometritis.

2 cl

FIELD: medicine.

SUBSTANCE: invention relates to field of veterinary medicine and is intended for treatment of mastitis in sheep. method includes introduction of medication, containing antibiotic and chemical therapeutic substance, at the background of subcutaneous introduction of oxytocin in dose 10 U two times with 12-hour interval and above-udder novocaine blockade in accordance with D.D.Logvinov, by double introduction of 0.25% novocaine solution in dose 0.5 ml per 1 kg of body weight, with 48-hour interval. Used is preparation, which contains antibiotic norfloxacin as antimicrobial preparation, and dioxydin as chemical therapeutic substance, and additionally 1,2-propyleneflycol, polyvinylpyrrolidone low-molecular, disodium salt of tetraacetic acid ethylenediamine (trilon B), hydrochloric acid (0.1 mol/l) to pH 4.5, water for injections with the following component ratio, wt %: dioxydin - 1.0; norfloxacin - 5.0; 1,2-propyleneflycol - 19.8; polyvinylpyrrolidone low-molecular - 0.2; disodium salt of tetraacetic acid ethylenediamine (trilon B) - 0.01; hydrochloric acid (0.1 mol/l) to pH 4.5-5.5; water for injections - to 100.0. Preparation is introduced intramuscularly in dose o.1 ml/kg of body weight two times per day until clinical recovery, for all forms of mastitis.

EFFECT: claimed invention makes it possible to provide expressed therapeutic effect.

2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science and aims at treating subclinical mastitis in cows. The method involves intracisternal administration of an activated physiologic saline. The activated physiologic saline is administered in the concentration of 600 mg/l in a dose of 20 ml after afternoon milking three days running. Additionally Trivyt 10 ml is intramuscularly injected on the first therapeutic day.

EFFECT: using the declared invention enables more effective treatment and reduced period of recovery.

2 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: analgesic preparation causing medication overuse headache are withdrawn; a detoxification therapy is conducted; an analgesic alternative is provided; a preventive medication and a behaviour therapy are applied. The preventive medication represents single intramuscular administration of xeomin into temporal muscles in a dose of 25 units in each frontal and occipital muscle in a dose of 12.5 units. The preventive medication follows the detoxification therapy.

EFFECT: considerable reduction of the recurrence number by relieving the reflex pericranial muscle and expression line tension.

1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to endocrinology, and deals with treatment of diabetes mellitus, complicated by accompanying diseases, in particular, by parasite invasions. For this purpose electro-activated water solutions of inorganic salts are introduced at the background of antihyperglycemic medications. On first 5 days solution of anolyte (EWS-A) with redox potential (RP) from +700 to +800 mV and with pH from 6.0 to 4.5, after which for 5 days introduced is catholyte solution (EWS-C) with RP from -400 to -600 mV and pH from 9.5 to 10.5; then for 10 days introduced are heated to +36°C - +37°C EWS-C and EWS-A are introduced with their alternation for 24 hours. In case of accompanying parasite invasion, EWS-A in combination with anti-parasitic vegetable medications in form of rectal microclysters for first 5 days of treatment is additionally introduced for first 5 days of treatment. EWS-C in combination with rectal microclysters with probiotic additives is introduced for the following 10 days. In case of detection of Opisthorchida, biltricide is introduced on the 15-th day in dose 75 mg/kg, and duodenal probing with anti-parasitic medication is carried out on the 16-th day. Starting with the 6-th day and to the completion of treatment (21-st day) fermented milk product "Narine" is administered in dose 1 tablespoon 3 times per day 30-40 minutes before meal.

EFFECT: mode of introducing electro-activated water solutions in complex with probiotics and anti-parasitic preparations provides efficient treatment of parasite invasions in combination with gradual normalisation of carbohydrate and lipid exchange in patients with diabetes mellitus.

2 cl, 2 ex, 4 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to biotechnology and can be used for suppressing viability of pathogenic leptospira. The method includes growing strains of bacteria "Bacillus subtilis TNP-3-DEP" and "Bacillus subtilis TNP-5-DEP". The grown strains are used for the preparation of a suspension. The obtained suspension, containing the strains of bacteria "Bacillus subtilis TNP-3-DEP" and "Bacillus subtilis TNP-5-DEP" in equal ratios with the concentration of 5×108 CFU in 1 ml, is introduced into vials with cultures of leptospira, incubated at specified process parameters with the registration of a result by the absence of leptospira in the sample.

EFFECT: invention makes it possible to extend the arsenal of anti-leptospirosis preparations.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the pharmaceutical industry, namely to a composition of immunity stimulation. The composition for immunity stimulation and/or immune protection enhancement contains a combination of an elder extract and at least one strain Lactobacillus paracasei, Lactobacillus casei, Lactobacillus bulgaricus or Streptococcus thermophilus taken in certain relations.

EFFECT: composition described above possesses the high immunomodulatory effect.

8 cl, 8 dwg, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to biotechnology. What is presented is a probiotic composition containing a probiotic ingredient, which is presented by Bifidobacterium longum R175 and one or two bacterial species specified in a group consisting of Lactobacillus rhamnosus R11, Lactobacillus helveticus R52 and Lactobacillus plantarum R1012, and a carrier composition. The above carrier composition contains mixture of prebiotics containing inulin and fructose, lactoferrin, inorganic salts, and glutathione as possible. There are also presented versions of the compositions in certain ratio of the above ingredients. What is also presented is a version of the composition containing mixture of probiotic ingredients consisting of Bifidobacterium longum R175 and Lactobacillus rhamnosus R11, a prebiotic ingredient, lacroferrin, inorganic salts and Saccharomyces boulardii. The above compositions are used for supporting and/or recovering the intestinal health and for preventing disbiosis of any origin in mammals, as well as in a method for improving a survival rate of the bacteria Bifidobacterium longum in the gastrointestinal tract.

EFFECT: group of inventions provides the effective colonisation of the gastrointestinal tract with the probiotic ingredients, causes the accompanying anti-inflammatory and immunomodulatory action.

20 cl, 4 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to lactic-acid bacteria strain used as a therapeutic agent for treating allergy, as well as to using the above strains for preparing a composition for treating allergy. There are presented the lactic-acid bacteria strain Lactobacillus plantarum CBS120663, the lactic-acid bacteria strain Lactobacillus plantarum CBS120664 and the lactic-acid bacteria strain Lactobacillus fermentum CBS120661. The strains possess an ability to elicit the Th1 and/or Th3 responses, and/or inhibit the Th2 responses, which can be defined by cytokine profiles induced in human peripheral blood mononuclear cells if incubated together with the above strains. What is also presented is using the above strains for preparing the composition for treating allergy.

EFFECT: group of inventions can be effectively used for relieving allergy in the patient.

11 cl, 9 tbl, 3 ex

FIELD: agriculture.

SUBSTANCE: method of application of feed additive for pigs, comprising lactic ferment based on consortium of live lactic acid and propionic acid bacteria of three complexes: the 1st of strains of lactic acid bacteria S. salivarius-LT-1, S. Thermophilus-LT9, LT10, LT11 and strain of propionic acid bacteria Propionibacterium freidenreichii-LT8 in the ratio of 1:3; 2nd of strains of lactic acid bacteria L. Plantarum-LT7, L. Acidophilus-LT12 and strain of propionic acid bacteria Propionibacterium freidenreichii-LT8 in the ratio of 2:1; 3rd of the strains of propionic acid bacteria Propionibacterium freidenreichii-LT8 and lactic acid bacteria S. salivarius-LT-1, L. Plantarum-LT7, S. Thermophilus-LT9, LT10, LT11, L. Acidophilus-LT12 in a ratio of 7:2, which is then used for fermenting pasteurized milk with fat content of 1.5-2.5% and a ratio of 1:30, and the additive is daily fed together with the combined feed, in addition the minerals are periodically added to the composition of the feed additive: potassium iodide - KI and sodium selenite - Na2SeO3, adding is carried out after every day of omission, alternating with potassium iodide and sodium selenite weekly during the fattening period, starting with the four months of age of the piglets, and potassium iodide is added in an amount of 0.46 mg and sodium selenite - in an amount of 0.44 mg, i.e. 0.2 mg of pure selenium, per 1 kg of dry matter of diet.

EFFECT: increase in live body weight due to increase in muscle tissue, improving the quality of meat by reducing the layer of subcutaneous fat, increase in total body resistance to diseases of pigs.

8 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to biotechnology. The method aims at preventing mycotoxicosis in horses. It provides adsorbing the preparation 'Sakhabactisubtil' representing a suspension of the bacterial strain Bacillus subtilis TNP-3-DEP and Bacillus subtilis TNP-5-DEP in equal proportions, adsorbed on oats, and feeding the animals with oats once a day at 10ml of 1kg of oats for 10 days.

EFFECT: invention provides normalising the intestinal microbiocenosis and increasing the animal's body weight.

1 tbl

FIELD: medicine.

SUBSTANCE: enterosorbent is administered in the morning in an S daily dose on an empty stomach daily for 1-3 months 2-3 hours before meals. Colonising the intestinal flora with a normal flora is ensured by daily 4-week roal administration of the liquid biocomplex Normoflorin 3 times a day in age doses; the first and second intakes involve the preparation Normoflorin L, and the third one - Normoflorin B.

EFFECT: effective treatment of allergic diseases by eliminating endogenous and exogenous toxic substances of various nature and reducing thereby body sensibilisation, providing extensive cleansing of the bowels from fermentation and putrifaction products, pathogenic and opportunistic flora, and ensuring natural immunity stimulation.

1 ex

FIELD: biotechnology.

SUBSTANCE: strain Bacillus lentus "GKPM-Obolensk" B-7150 - producer of bacteriocin-like substance of broad spectrum of antimicrobial action is proposed, having molecular weight according to data of SDS-PAGE of about 4 kDa. Also the method of obtaining bacteriocin-like substance is provided, comprising submerged cultivation of Bacillus lentus "GKPM-Obolensk" B-7150 at a temperature 29-30°C in carbohydrate-yeast medium based on inorganic source of amino nitrogen with a limit of oxygen and carbohydrate. Isolation of bacteriocin-like substance from acellular fluid is carried out using dichloromethane or silica gel type adsorbent, and from the surface of cells - using ethanol. Then the fractions are combined and dried.

EFFECT: strain has antagonistic activity against coliform and other gram-negative bacteria and some species of gram-positive microorganisms.

2 cl, 3 dwg, 5 tbl, 7 ex

FIELD: biotechnology, microbiology, medicine.

SUBSTANCE: invention relates to the strain Lactobacillus paracasei CNCM I-2116 used for diarrhea prophylaxis causing by pathogenic microorganisms. Supernatant of this strain culture elicits ability to prevent colonization of intestine with pathogenic microorganisms causing diarrhea also and this strain is designated for preparing agent used for prophylaxis and/or treatment of disorders associated with diarrhea. Agent for oral administration represents therapeutically effective dose of the strain L. paracasei CNCM I-2116 or supernatant of its culture and acceptable foodstuff. Invention provides the enhanced viability of the strain in its applying and effectiveness in prophylaxis of adhesion to intestine cells and invasion to intestine cells of pathogenic microorganisms causing diarrhea.

EFFECT: valuable medicinal properties of strain.

5 cl, 8 dwg, 10 ex

Up!